LW6

**LW6** is an (aryloxyacetylamino)benzoic acid derivative developed as a small molecule inhibitor of **hypoxia-inducible factor-1 alpha (HIF-1α)**[1][2][3]. LW6 selectively inhibits HIF-1α accumulation under hypoxic conditions in cancer cells, which has implications for reducing tumor growth and overcoming chemoresistance[1][2]. Its primary mechanism is direct inhibition of **malate dehydrogenase-2 (MDH2)** in the mitochondria, disrupting the Krebs cycle resulting in reduced NADH and FADH2 production, a decrease in oxygen consumption, and secondary destabilization/degradation of HIF-1α[3]. LW6 rapidly converts to an active metabolite, **(4-adamantan-1-yl-phenoxy)acetic acid (APA)**, in vivo, which is also pharmacologically active[1]. LW6 induces apoptosis in hypoxic cells through mitochondrial membrane depolarization and increased reactive oxygen species (ROS)[2]. It is primarily in **preclinical development** for oncology indications (e.g., solid tumors), with reported low toxicity and efficacy in animal xenograft models[1][2][3].